Printer Friendly

CYTOCARE FILES 510(k) SUBMISSION FOR LASER CATHETER FOR LASER SURGERY OF UROLOGICAL TISSUES

 CYTOCARE FILES 510(k) SUBMISSION FOR LASER CATHETER
 FOR LASER SURGERY OF UROLOGICAL TISSUES
 IRVINE, Calif., May 11 /PRNewswire/ -- Cytocare Inc. (NASDAQ: CYTI) announced today that it has received notification from the Food and Drug Administration (FDA) that its 510(k) submission to market the Cytocare laser catheter has been accepted for filing. FDA review of the filing is in process.
 The Cytocare laser catheter is designed for use with continuous wave Nd:Yag lasers for incision, excision, ablation and coagulation of general urological tissues. The laser catheter is intended for use with or without an endoscope, laparoscope, cystoscope or other viewing device.
 Cytocare is developing a family of diagnostic and therapeutic pharmaceuticals and devices for prostate disease. Medstone International Inc., its manufacturing subsidiary, serves urology with lithotripsy products and procedures.
 -0- 5/11/92
 /CONTACT: Jeannine Cormane of Cytocare, 714-587-0500/
 (CYTI) CO: Cytocare Inc.; Medstone International Inc. ST: California IN: MTC SU:


KJ-AL -- LA003 -- 8452 05/11/92 09:07 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 11, 1992
Words:162
Previous Article:CYTOCARE INC. ELECTS NEW DIRECTOR
Next Article:THE CHEROKEE GROUP ANNOUNCES INTEREST RATE ON NOTES HAS BEEN RESET


Related Articles
FIRST NONSURGICAL LASER TREATMENT OF RAPID HEARTBEAT PERFORMED; ANGEION ABLATION SYSTEM OFFERS CURE
PHOENIX LASER SYSTEMS FILES U.S. PATENT FOR OPHTHALMIC WORKSTATION
CABOT MEDICAL/SURGITEK ANNOUNCE NEW UROLOGICAL LASER FIBER
FDA Approves Spectranetics' Advanced Catheter Designed to Improve Effectiveness of Coronary Angioplasty
Spectranetics Announces CE Mark Approval for the Vitesse COS Coronary Laser Catheter.
CardioFocus, Inc. Announces FDA 510(k) Clearance of its Diode Laser for Surgical Use; Total System Now Cleared for Sale in the U.S.
Spectranetics Receives 510(k) Clearance for Laser Technology to Treat Total Occlusions in Leg Arteries; Company Plans to Launch CLiRpath(TM) Product...
Study Investigators Perform First Successful Peripheral Procedures With CLiRpath Extreme Excimer Laser Catheters Following April 29 510(k) Market...
Spectranetics Launches CLiRpath 2.5 Turbo Catheter for More Efficient Treatment of Long Total Occlusions in the Superficial Femoral Artery.
Spectranetics' Full CLiRpath Product Line Receives FDA Clearance For 80Hz Lasing Capability.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters